FRONTEO has launched a project with Otsuka Pharmaceutical to jointly pursue the discovery of target molecules in renal diseases using DDAIF, an AI-powered drug discovery support service.
FRONTEO was showing a bid indication and announced that it had launched on the 27th a co-creation project with Otsuka Pharmaceutical, an Otsuka Holdings group company, to discover target molecules in renal diseases.
The project will use FRONTEO’s equation-driven AI “KIBIT” and proprietary analytical methods to identify highly novel target molecule candidates for diseases designated by Otsuka Pharmaceutical. The company plans to validate the relevant scientific evidence for the identified candidates from multiple perspectives and develop hypotheses regarding the relationships between the target molecules and diseases and their mechanisms of action.
Through this initiative, the companies aim to support the discovery of new drug targets beyond the extension of existing knowledge and create innovative therapies in the renal disease field.